Multi-center study confirms value of QIAGEN’s QuantiFERON®-TB Gold Plus
Feb 15 2016

Multi-center study confirms value of QIAGEN’s QuantiFERON®-TB Gold Plus

Cross-European trial shows enhanced sensitivity of fourth-generation test for tuberculosis infection

Hilden, Germany, February 15, 2016 QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) today announced a major published study evaluating its novel QuantiFERON®-TB Gold Plus, the fourth-generation of QIAGEN’s industry-leading test for tuberculosis (TB) infection. Results of the multi-center study, published ahead of print in the peer-reviewed European Respiratory Journal on February 12, confirmed that QuantiFERON-TB Gold Plus demonstrates excellent performance,– with a diagnostic sensitivity estimated at  88% and a specificity of 97%. Notably, among subjects co-infected with HIV and TB, the QuantiFERON-TB Gold Plus result was positive in all of them, demonstrating 100% sensitivity in this challenging patient population.

“This publication by leading European experts provides the medical community with independent confirmation of the excellent performance of QuantiFERON-TB Gold Plus as demonstrated in our validation and registration studies,” said Dr. Masae Kawamura, Senior Director of Medical and Scientific Affairs for QIAGEN. “Introduced in Europe in 2015, QuantiFERON-TB Gold Plus helps clinicians get accurate, reliable results to detect latent TB infection and to protect vulnerable patients from active TB. The authors also noted the potential value of additional clinical information provided by the proprietary CD8 T-cell technology in QuantiFERON TB-Gold Plus.”

The study of QuantiFERON TB-Gold Plus was led by Dr. Daniela Cirillo, Director of the Supranational Reference Laboratory at the San Raffaele Scientific Institute in Milan, and included leading experts from six sites across Europe. The investigators assessed the sensitivity and specificity of QuantiFERON-TB Gold Plus by testing 225 people, 119 patients with active TB and 106 low-risk control subjects. The active TB group consisted of patients with TB that was confirmed microbiologically (either by nucleic acid amplification or culture) and included immunocompromised individuals, such as people living with HIV infection.

The authors also commented on the CD8 T-cell technology of QuantiFERON-TB Gold Plus, the only test for TB infection that offers the ability to distinguish between CD4 and CD8 T-cell responses. The investigators found a statistically significant difference in responses for the two T-cell types and suggested further studies. “The novel CD8 technology is providing interesting signals on potential additional interpretation of the TB infection spectrum and risk assessment. Studies are needed to further explore this,” Dr. Cirillo said. Around 20 studies of QuantiFERON-TB Gold Plus have been initiated to date, and QIAGEN expects further publications in 2016.

QIAGEN partners with governments and health organizations around the world to fight tuberculosis – and continues to develop innovative new technologies. QuantiFERON-TB Gold is the modern standard for accuracy in latent TB infection diagnosis – faster, less labor-intensive and more accurate than the tuberculin skin test. QuantiFERON-TB-Gold’s clinical reliability and simpler administration enhance the accuracy of screening and improve the cost-effectiveness of TB control. In 2015 QIAGEN launched QuantiFERON-TB Gold Plus in Europe and other markets as a fourth-generation test with CE-IVD marking. To date, more than 20 million tests using QuantiFERON-TB technology have been distributed globally.

 

To learn more about QuantiFERON-TB Gold Plus and QuantiFERON-TB Gold, please visit www.QuantiFERON.com.

 

About QIAGEN

QIAGEN N.V., a Netherlands-based holding company, is the leading global provider of Sample to Insight solutions to transform biological materials into valuable molecular insights. QIAGEN sample technologies isolate and process DNA, RNA and proteins from blood, tissue and other materials. Assay technologies make these biomolecules visible and ready for analysis. Bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. Automation solutions tie these together in seamless and cost-effective molecular testing workflows. QIAGEN provides these workflows to more than 500,000 customers around the world in Molecular Diagnostics (human healthcare), Applied Testing (forensics, veterinary testing and food safety), Pharma (pharmaceutical and biotechnology companies) and Academia (life sciences research). As of December 31, 2015, QIAGEN employed approximately 4,600 people in over 35 locations worldwide. Further information can be found at http://www.qiagen.com.

 

Certain statements contained in this press release may be considered forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. To the extent that any of the statements contained herein relating to QIAGEN's products, markets, strategy or operating results, including without limitation its expected operating results, are forward-looking, such statements are based on current expectations and assumptions that involve a number of uncertainties and risks. Such uncertainties and risks include, but are not limited to, risks associated with management of growth and international operations (including the effects of currency fluctuations, regulatory processes and dependence on logistics), variability of operating results and allocations between customer classes, the commercial development of markets for our products to customers in academia, pharma, applied testing and molecular diagnostics; changing relationships with customers, suppliers and strategic partners; competition; rapid or unexpected changes in technologies; fluctuations in demand for QIAGEN's products (including fluctuations due to general economic conditions, the level and timing of customers' funding, budgets and other factors); our ability to obtain regulatory approval of our products; difficulties in successfully adapting QIAGEN's products to integrated solutions and producing such products; the ability of QIAGEN to identify and develop new products and to differentiate and protect our products from competitors' products; market acceptance of QIAGEN's new products and the integration of acquired technologies and businesses. For further information, please refer to the discussions in reports that QIAGEN has filed with, or furnished to, the U.S. Securities and Exchange Commission (SEC).

FOLLOW US ON SOCIAL MEDIA

Share this page